Acquisition of Fougera Pharmaceuticals
Our attorneys represented Novartis on the purchase, by generics division Sandoz, of specialty dermatology generics company Fougera Pharmaceuticals for $1.525 billion in an all cash transaction. The sellers were a consortium of private equity funds led by Nordic Capital, DLJ Merchant Banking (a Credit Suisse affiliate) and Avista Capital Partners.
This acquisition improved Sandoz’s ability to help patients and customers around the world by providing easier access to high quality, affordable dermatological medicines. With this move, Sandoz will also became the number one generic dermatology medicines company both globally and in the US.